Latest News and Press Releases
Want to stay updated on the latest news?
-
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
-
Leapfrog Bio announced AACR presentation describing the discovery, characterization, and clinical development plan for lead drug LFB-190.
-
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
-
CRANBURY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
-
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
-
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Immuneering Recognizes Melanoma Awareness Month
-
CRANBURY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...